|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2022―May―23 |
Has the pandemic changed treatment strategy in multiple sclerosis? |
Gabriel Bsteh, Katharina Riedl, Nik Krajnc, Barbara Kornek, Fritz Leutmezer, Stefan Macher, et al. (+3) Paulus Rommer, Gudrun Zulehner, Thomas Berger |
2 |
[GO] |
2022―May―21 |
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters |
William L. Conte, Lilian Golzarri-Arroyo |
3 |
[GO] |
2022―May―19 |
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience |
Ahmed Essmat |
4 |
[GO] |
2022―May―19 |
Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East |
Raed Alroughani, Jihad Said Inshasi, Jasem Al-Hashel, Jaber Alkhaboury, Abdullah Alsalti, Reem Al Suwaidi, et al. (+2) Loqman H. Hassino, Samar Farouk Ahmed |
5 |
[GO] |
2022―May―19 |
Epidemiology of COVID-19 in Patients with MS: A Hospital-Based Registry |
Sharareh Eskandarieh, Nasim Rezaeimanesh, Hora Heydari, Mohammad Hossein Harirchian |
6 |
[GO] |
2022―May―19 |
Association of Multiple Sclerosis and COVID-19 Infection: A Case Report |
Ismail Ibrahim Ismail, Jasem Al-Hashel, Raed Alroughani, Samar Farouk Ahmed |
7 |
[GO] |
2022―May―19 |
The impact of COVID-19 on people with multiple sclerosis: A comparison of Italian and United States cohorts |
Carolyn E. Schwartz, Bruce D. Rapkin, Simona Bonavita, Michela Bossa, Maria Chiara Buscarinu, Maria Grazia Grasso, et al. (+3) Maria Luca, Agostino Nozzolillo, Ugo Nocentini |
8 |
[GO] |
2022―May―19 |
Medication Adherence Among Patients with Multiple Sclerosis During the COVID-19 Pandemic: Perspective from the Near East Region |
Murad Al-Naqshbandi, Hoda Joudi, Abed Raki |
9 |
[GO] |
2022―May―19 |
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets |
Bassem I Yamout, Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, et al. (+4) Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl |
10 |
[GO] |
2022―May―19 |
Real-world experience on the use of COVID-19 vaccination in patients with multiple sclerosis treated with Cladribine tablets in the Gulf region |
Jihad Inshasi, Amir Boshra, Joseph Youssef |
11 |
[GO] |
2022―May―19 |
COVID-19 Vaccination in People with Multiple Sclerosis. the Kuwait Experience |
Raed Alroughani, Jasem Al-Hashel, Fathi Abokalawa, Malak Almojel, Samar Farouk Ahmed |
12 |
[GO] |
2022―May―19 |
Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study |
Nahad Sedaghat, Masoud Etemadifar, Hosein Nouri, Amir Parsa Abhari, Shiva Maleki, Alireza Amin, Mehri Salari |
13 |
[GO] |
2022―May―19 |
Humoral Immune Response to SARS-CoV-2 Vaccination in MS Patients |
Celia Oreja-Guevara, Judit Díaz-Díaz, Elda Alba Suárez, Irene Gómez-Estévez, Johnny Quezada Sánchez, Cristina Bullón-Sánchez, et al. (+4) Matilde Castro-Hernández, Eduardo Martinez-Pérez, Silvia O´Connor Pérez, Elvira Baos Muñoz |
14 |
[GO] |
2022―May―19 |
The Psychological Effect of COVID19 Pandemic on Neuromyelitis Optica Spectrum Disorder Patients and Their Attitude Change After a Year of the Pandemic in Isfahan, Iran. |
Roshanak Mehdipour Dastjerdi, Fereshteh Ashtari |
15 |
[GO] |
2022―May―17 |
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal. |
João Moura, Henrique Nascimento, Inês Ferreira, Raquel Samões, Catarina Teixeira, Dina Lopes, et al. (+4) Daniela Boleixa, Ana Paula Sousa, Ernestina Santos, Ana Martins Silva |
16 |
[GO] |
2022―May―10 |
Longitudinal humoral response in MS patients treated with Cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine |
Livnat Brill, Ariel Rechtman, Alla Shifrin, Ayal Rozenberg, Svetlana Afanasiev, Omri Zveik, et al. (+3) Nitzan Haham, Neta Levin, Adi Vaknin-Dembinsky |
17 |
[GO] |
2022―May―06 |
The influence of COVID-19 pandemic lockdown on the physical activity of people with multiple sclerosis. The role of online training |
Mariola Matysiak, Małgorzata Siger, Agata Walczak, Agnieszka Ciach, Mateusz Jonakowski, Mariusz Stasiołek |
18 |
[GO] |
2022―May―06 |
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies |
Asya I. Wallach, Matthew Schiebel, Mary Ann Picone |
19 |
[GO] |
2022―Apr―25 |
Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders |
Alessandro Dinoto, Matteo Gastaldi, Raffaele Iorio, Sofia Marini, Valentina Damato, Antonio Farina, et al. (+8) Marco Zoccarato, Elia Sechi, Francesca Pinna, Giorgia Teresa Maniscalco, Ruggero Barnabei, Luigi Zuliani, Sergio Ferrari, Sara Mariotto |
20 |
[GO] |
2022―Apr―13 |
Long term persistence of SARS-CoV-2 humoral response in Multiple Sclerosis subjects |
Giorgia Teresa Maniscalco, Anne Lise Ferrara, Antonietta Liotti, Valentino Manzo, Maria Elena Di Battista, Simona Salvatore, et al. (+10) Daniela Graziano, Assunta Viola, Gerardino Amato, Ornella Moreggia, Daniele Di Giulio Cesare, Gennaro Alfieri, Walter Di Iorio, Gennaro Della Rocca, Vincenzo Andreone, Veronica De Rosa |
21 |
[GO] |
2022―Apr―11 |
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies? |
Gavin Giovannoni |
22 |
[GO] |
2022―Apr―10 |
Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab |
Mario Habek, Dominik Piskač, Tereza Gabelić, Barbara Barun, Ivan Adamec, Magdalena Krbot Skorić |
23 |
[GO] |
2022―Apr―10 |
The impact of the COVID-19 pandemic on physical therapy practice for people with multiple sclerosis: A multicenter survey study of the RIMS network |
Turhan Kahraman, Kamila Rasova, Johanna Jonsdottir, Carme Santoyo Medina, Daphne Kos, Susan Coote, et al. (+8) Andrea Tacchino, Tori Smedal, Ellen Christin Arntzen, Gillian Quinn, Yvonne Learmonth, Ludovico Pedulla, Lousin Moumdjian, Alon Kalron |
24 |
[GO] |
2022―Apr―06 |
Autoimmune encephalitis associated with COVID-19: A systematic review |
Fardin Nabizadeh, Mohammad Balabandian, Fatemeh Sodeifian, Negin Rezaei, Mohammad Reza Rostami, Abdorreza Naser Moghadasi |
25 |
[GO] |
2022―Apr―06 |
HUMORAL RESPONSE TO SARS-COV-2 INFECTION AND VACCINES AGAINST COVID-19 IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDERS: IMPACT OF IMMUNOSUPPRESSIVE TREATMENT |
Vanja Jovicevic, Jovana Ivanovic, Nikola Momcilovic, Marko Andabaka, Olivera Tamas, Nikola Veselinovic, et al. (+5) Danica Cujic, Marija Gnjatovic, Sarlota Mesaros, Tatjana Pekmezovic, Jelena Drulovic |
26 |
[GO] |
2022―Mar―30 |
The Humoral Response to SARS-COV-2 Vaccines in MS Patients: A Case Series Exploring the Impact of DMT, Lymphocyte Count, Immunoglobulins, and Vaccine Type |
Collin Jakubecz, Xiaochun Susan Zhang, Sophia Woodson, Alessandro Serra, Hesham Abboud |
27 |
[GO] |
2022―Mar―26 |
The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: a meta-analysis |
Altieri Manuela, Capuano Rocco, Bisecco Alvino, d'Ambrosio Alessandro, Buonanno Daniela, Tedeschi Gioacchino, et al. (+2) Santangelo Gabriella, Gallo Antonio |
28 |
[GO] |
2022―Mar―13 |
COVID-19 vaccine associated demyelination & its association with MOG antibody |
Netravathi M, Dhamija K, Manisha Gupta, Arina Tamborska, Nalini A, VV Holla, et al. (+11) Nitish LK, Deepak Menon, Pal PK, Seena V, Yadav R, Ravindranadh M, Arshad F, Saini J, Mahadevan A, Tom Solomon, Bhagteshwar Singh |
29 |
[GO] |
2022―Mar―12 |
Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis |
Sammita Satyanarayan, Neha Safi, Tali Sorets, Susan Filomena, Yinan Zhang, Sylvia Klineova, et al. (+8) Michelle Fabian, Sam Horng, Stephanie Tankou, Aaron Miller, Stephen Krieger, Fred Lublin, James Sumowski, Ilana Katz Sand |
30 |
[GO] |
2022―Mar―11 |
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies |
Tyler E Smith, Maya Madhavan, Daniel Gratch, Aneek Patel, Valerie Saha, Carrie Sammarco, et al. (+8) Zoe Rimler, Guadalupe Zuniga, Dunia Gragui, Leigh Charvet, Gary Cutter, Lauren Krupp, Ilya Kister, Lana Zhovtis Ryerson |
31 |
[GO] |
2022―Mar―07 |
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients |
Hamza Mahmood Bajwa, Frederik Novak, Anna Christine Nilsson, Christian Nielsen, Dorte K. Holm, Kamilla Østergaard, et al. (+9) Agnes Hauschultz Witt, Keld-Erik Byg, Isik S. Johansen, Kristen Mittl, William Rowles, Scott S. Zamvil, Riley Bove, Joseph J. Sabatino, Tobias Sejbaek |
32 |
[GO] |
2022―Mar―05 |
COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis |
Naghmeh Abbasi, Fereshteh Ghadiri, Abdorreza Naser Moghadasi, Amirreza Azimi, Samira Navardi, Hora Heidari, et al. (+2) Maryam Karaminia, Mohammad Ali Sahraian |
33 |
[GO] |
2022―Mar―04 |
Six-month humoral response to mRNA SARS-CoV-2 vaccination in Patients with Multiple Sclerosis treated with Ocrelizumab and Fingolimod |
Rocco Capuano, Alvino Bisecco, Miriana Conte, Giovanna Donnarumma, Manuela Altieri, Elena Grimaldi, et al. (+6) Gianluigi Franci, Annalisa Chianese, Massimiliano Galdiero, Nicola Coppola, Gioacchino Tedeschi, Antonio Gallo |
34 |
[GO] |
2022―Mar―03 |
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications |
Elle Levit, Erin E. Longbrake, Sharon S Stoll |
35 |
[GO] |
2022―Feb―26 |
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran |
Sepideh Paybast, Seyed Amir Hejazi, Payam Molavi, Mohammad Amin Habibi, Abdorreza Naser Moghadasi |
36 |
[GO] |
2022―Feb―19 |
Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review |
Omid Mirmosayyeb, Elham Moases Ghaffary, Sara Bagherieh, Mahdi Barzegar, Mohammad Sadegh Dehghan, Vahid Shaygannejad |
37 |
[GO] |
2022―Feb―19 |
COVID-19 in neuromyelitis optica spectrum disorder patients in Poland. |
Aleksandra Podlecka-Piętowska, Krzysztof Barć, Agata Denisiuk, Monika Nojszewska, Beata Zakrzewska-Pniewska |
38 |
[GO] |
2022―Feb―19 |
Real-world data about the side effects of SARS-CoV-2 vaccinations can be obtained only from representative samples undergoing comprehensive investigations |
Josef Finsterer |
39 |
[GO] |
2022―Feb―13 |
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis |
Ethel Ciampi, Reinaldo Uribe-San-Martin, Bernardita Soler, Lorena García, Jorge Guzman, Carolina Pelayo, et al. (+5) Lukas Jürgensen, Ignacio Guzman, Francisco Vera, Lorna Galleguillos, Claudia Cárcamo |
40 |
[GO] |
2022―Feb―08 |
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies |
Mario Habek, Cvetić Željko, Ana Savić Mlakar, Krešo Bendelja, Dunja Rogić, Ivan Adamec, et al. (+3) Barbara Barun, Tereza Gabelić, Magdalena Krbot Skorić |
41 |
[GO] |
2022―Jan―25 |
Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: a rapid systematic review |
Amin Zarghami, Mohammad A. Hussain, Julie A. Campbell, Chigozie Ezegbe, Ingrid van der Mei, Bruce V. Taylor, Suzi B. Claflin |
42 |
[GO] |
2022―Jan―24 |
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - a pilot study |
Moser Tobias, Otto Ferdinand, O′Sullivan Ciara, Hitzl Wolfgang, Pilz Georg, Harrer Andrea, et al. (+2) Trinka Eugen, Wipfler Peter |
43 |
[GO] |
2022―Jan―24 |
Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise |
Omid Razi, Bakhtyar Tartibian, Ana Maria Teixeira, Nastaran Zamani, Karuppasamy Govindasamy, Katsuhiko Suzuki, et al. (+2) Ismail Laher, Hassane Zouhal |
44 |
[GO] |
2022―Jan―19 |
To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England |
Bastian Tugemann, Navid Manouchehri, Olaf Stuve |
45 |
[GO] |
2022―Jan―11 |
7Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis |
Recai Türkoğlu, Nesrin Baliç, Tuğçe Kızılay, Ruziye Erol, Ece Akbayır, Vuslat Yılmaz, Erdem Tüzün |
46 |
[GO] |
2022―Jan―10 |
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies |
Serkan Ozakbas, Cavid Baba, Yavuz Dogan, Sumeyye Cevik, Sinem Ozcelik, Ergi Kaya |
47 |
[GO] |
2022―Jan―08 |
Clinical Characteristics and Outcomes of Multiple Sclerosis Patients with COVID-19 in Toronto, Canada |
Jacqueline M. Solomon, Ashley Jones, Marika Hohol, Kristen M. Krysko, Alexandra Muccilli, Alexandra Roll, et al. (+6) Dalia Rotstein, Raphael Schneider, Daniel Selchen, Reza Vosoughi, Stefan D. Baral, Jiwon Oh |
48 |
[GO] |
2022―Jan―04 |
Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic |
Elle Levit, Inessa Cohen, Megan Dahl, Keith Edwards, Bianca Weinstock-Guttman, Toshinari Ishikawa, et al. (+11) Katelyn Kavak, Victoria Leavitt, Katie Nelson, Kaho Onomichi, Amit Bar-Or, Christopher Perrone, Claire Riley, Shruthi Venkatesh, Philip L. De Jager, Zongqi Xia, Erin E. Longbrake |
49 |
[GO] |
2022―Jan―04 |
Surviving a global pandemic: The experience of depression, anxiety, and loneliness among individuals with multiple sclerosis |
L. Strober, E. Weber, A. Lequerica, N. Chiaravalloti |
50 |
[GO] |
2021―Dec―20 |
Pandemic-associated mental health changes in youth with neuroinflammatory disorders |
Lindsey M Logan, Samantha Stephens, Beyza Ciftci-Kavaklioglu, Tara Berenbaum, Mina Ly, Giulia Longoni, E Ann Yeh |
51 |
[GO] |
2021―Dec―18 |
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects |
Giorgia Teresa Maniscalco, Valentino Manzo, Anne Lise Ferrara, Alessandro Perrella, Mariaelena Di Battista, Simona Salvatore, et al. (+15) Daniela Graziano, Assunta Viola, Gerardino Amato, Ornella Moreggia, Daniele Di Giulio Cesare, Stefano Barbato, Giovanna Servillo, Katia Longo, Mario Di Giovanni, Barbara Scarpati, Simona Maria Muggianu, Giuseppe Longo, Giuseppe Russo, Vincenzo Andreone, Veronica De Rosa |
52 |
[GO] |
2021―Dec―05 |
COVID-19 Vaccine Intent in Appalachian Patients with Multiple Sclerosis |
Hongyan Wu, Melanie Ward, Ashlyn Brown, Erica Blackwell, Amna Umer |
53 |
[GO] |
2021―Dec―05 |
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England |
Afagh Garjani, Sameer Patel, Dhiren Bharkhada, Waqar Rashid, Alasdair Coles, Graham R Law, Nikos Evangelou |
54 |
[GO] |
2021―Dec―04 |
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis |
David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson |
55 |
[GO] |
2021―Dec―02 |
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data |
Samantha Epstein, Zongqi Xia, Annie Lee, Megan Dahl, Keith Edwards, Elle Levit, et al. (+10) Erin E. Longbrake, Christopher Perrone, Katelyn Kavak, Bianca Weinstock-Guttman, Fatoumata Diallo, Adelle Ricci, Claire Riley, Philip L. De Jager, Rebecca Farber, Sarah F. Wesley |
56 |
[GO] |
2021―Nov―30 |
Characteristics of COVID-19 in patients with multiple sclerosis |
Fereshteh Ghadiri, Mohammad Ali Sahraian, Vahid Shayegannejad, Fereshteh Ashtari, Hamidreza Ghalyanchi, Seyed Mohammad Baghbanian, et al. (+10) Hossein Mojdehipanah, Nastaran Majdi-Nasab, Samaneh Hosseini, Maryam Poursadeghfard, Nahid Beladimoghadam, Nazanin Razazian, Saeideh Ayoubi, Nasim Rezaeimanesh, Sharareh Eskandarieh, Abdorreza Naser Moghadasi |
57 |
[GO] |
2021―Nov―30 |
Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod |
Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek |
58 |
[GO] |
2021―Nov―23 |
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: to wait and repopulate? |
Z.L.E. van Kempen, L. Wieske, E.W. Stalman, L.Y.L Kummer, P.J. van Dam, A.G. Volkers, et al. (+15) L. Boekel, A.A. Toorop, E.M.M. Strijbis, S.W. Tas, G.J. Wolbink, M. Löwenberg, C. van Sandt, A. ten Brinke, N.J.M. Verstegen, M. Steenhuis, T.W. Kuijpers, S.M. van Ham, T. Rispens, F. Eftimov, J. Killestein |
59 |
[GO] |
2021―Nov―22 |
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD |
Alessandro Dinoto, Elia Sechi, Sergio Ferrari, Alberto Gajofatto, Riccardo Orlandi, Paolo Solla, et al. (+9) Alessandra Maccabeo, Giorgia Teresa Maniscalco, Vincenzo Andreone, Arianna Sartori, Paolo Manganotti, Sarah Rasia, Ruggero Capra, Chiara Rosa Mancinelli, Sara Mariotto |
60 |
[GO] |
2021―Nov―22 |
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: same story, different vaccine |
Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, Noushin Lotfi, Ahmad Chitsaz, Reza Khorvash, et al. (+4) Hamed Zolfaghari, Alireza Ghasemi Movaghar, Mohammad Pourabbas, Mehri Salari |
61 |
[GO] |
2021―Nov―19 |
The Turkish experience of Covid-19 Infection in people with NMOSD and MOGAD: a milder course? |
Sedat Sen, Asli Tuncer, Serkan Ozakbas, Cihat Uzunkopru, Cavid Baba, Serkan Demir, et al. (+31) Yesim Beckmann, Haluk Gumus, Gokhan Arslan, Ahmet Kasim Kilic, Ayse Altintas, Nur Yuceyar, Omer Faruk Turan, Melih Tutuncu, Murat Terzi, Pinar Acar, Destan Bunul, Belgin Petek Balci, Levent Sinan Bir, Mesrure Koseoglu, Semra Mungan, Tuncay Gunduz, Ipek Gungor Dogan, Dilcan Kotan, Ugur Uygunoğlu, Ozgul Ekmekci, Meltem Demirkiran, Ozden Kamisli, Sibel Canbaz Kabay, Yusuf Tamam, Sami Omerhoca, Serhan Sevim, Sibel Guler, Murat Kurtuncu, Husnu Efendi, Rana Karabudak, Aksel Siva |
62 |
[GO] |
2021―Nov―18 |
B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study |
William L. Conte |
63 |
[GO] |
2021―Nov―10 |
A year with the fear of COVID-19 in Multiple Sclerosis Patients: Examination of depression, sleep quality and quality of life before and after the pandemic |
Kubra Yeni, Zeliha Tulek, Murat Terzi |
64 |
[GO] |
2021―Nov―10 |
COVID-19 outcomes in Persons with Multiple Sclerosis treated with Rituximab |
Rajesh B Iyer, Raghavendra S, Javeria Nooraine M, Jaychandran R |
65 |
[GO] |
2021―Nov―09 |
Humoral and T-Cell Responses to SARS-CoV-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab |
J.D. Katz, A.J. Bouley, R.M. Jungquist, E.A. Douglas, I.L. O'Shea, E.S. Lathi |
66 |
[GO] |
2021―Nov―03 |
¿Can COVID-19 exacerbate Multiple Sclerosis symptoms? A case series analysis. |
Gloria Michelena, Magdalena Casas, María Bárbara Eizaguirre, María Cecilia Pita, Leila Cohen, Ricardo Alonso, et al. (+2) Orlando Garcea, Berenice A Silva |
67 |
[GO] |
2021―Nov―01 |
The study of COVID-19 infection following vaccination in patients with multiple sclerosis |
Fereshteh Ghadiri, Mohammad Ali Sahraian, Amirreza Azimi, Abdorreza Naser Moghadasi |
68 |
[GO] |
2021―Nov―01 |
COVID-19 Susceptibility and Outcomes among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Review and Meta-Analysis |
Mahdi Barzegar, Omid Mirmosayyeb, Narges Ebrahimi, Sara Bagherieh, Alireza Afshari-Safavi, Ali Mahdi Hosseinabadi, et al. (+2) Vahid Shaygannejad, Nasrin Asgari |
69 |
[GO] |
2021―Oct―25 |
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis |
Livnat Brill, Ariel Rechtman, Omri Zveik, Nitzan Haham, Netta Levin, Alla Shifrin, et al. (+2) Ayal Rozenberg, Adi Vaknin-Dembinsky |
70 |
[GO] |
2021―Oct―25 |
Safety of Natalizumab reinfusion in Multiple Sclerosis patients during active Sars-Cov2 infection |
D. Landi, G. Cola, V. Mantero, R. Balgera, L. Moiola, A. Nozzolillo, et al. (+8) V. Dattola, L. Sinisi, R. Fantozzi, S. Di Lemme, D. Centonze, G. Mataluni, C.G. Nicoletti, G.A. Marfia |
71 |
[GO] |
2021―Oct―22 |
COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders |
Vanja Jovicevic, Jovana Ivanovic, Marko Andabaka, Olivera Tamas, Nikola Veselinovic, Nikola Momcilovic, et al. (+3) Sarlota Mesaros, Tatjana Pekmezovic, Jelena Drulovic |
72 |
[GO] |
2021―Oct―19 |
COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: what we know by May 2021 |
Saba Naghavi, Aryan Kavosh, Iman Adib, Vahid Shaygannejad, Sina Arabi, Maryam Rahimi, et al. (+2) Shahbanoo Mazaheri, Fereshteh Ashtari |
73 |
[GO] |
2021―Oct―19 |
Relationships between changes in daily occupations and health-related quality of life in persons with multiple sclerosis during the COVID-19 pandemic |
Yael Goverover, Michelle H. Chen, Amanda Botticello, Gerald T. Voelbel, Grace Kim, John DeLuca, Helen M. Genova |
74 |
[GO] |
2021―Oct―14 |
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 |
Yara D Fragoso, Sidney Gomes, Marcus Vinicius M Gonçalves, Euldes Mendes Junior, Bianca Etelvina S de Oliveira, Cristiane Franklin Rocha, et al. (+4) Gutemberg A Cruz dos Santos, Carlos Bernardo Tauil, Raquel Vassao Araujo, Jean Pierre S Peron |
75 |
[GO] |
2021―Oct―12 |
Sociodemographic and clinical factors associated with depression, anxiety, and general mental health in people with multiple sclerosis during the COVID-19 pandemic |
Lauren Uhr, Dylan R. Rice, Farrah J. Mateen |
76 |
[GO] |
2021―Oct―09 |
COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register |
Middleton RM, Craig EM, Rodgers WJ, Tuite-Dalton K, Garjani A, Evangelou N, et al. (+15) das Nair R, Hunter R, Tallantyre EC, Cauchi M, Cairn C, Paling D, Fuller S, McDonnell G, Petherham K, Liu B, Nock U, Ingram G, Brownlee W, Taylor J, Nicholas R |
77 |
[GO] |
2021―Sep―28 |
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis |
Mark S. Freedman, Dominic Jack, Zuzana Murgašová, Milorad Todorović, Andrea Seitzinger |
78 |
[GO] |
2021―Sep―28 |
Impact of COVID-19 Public Health Measures on Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders in Children |
Matsanga Leyila Kaseka, Mina Ly, Carmen Yea, Giulia Longoni, E. Ann Yeh |
79 |
[GO] |
2021―Sep―27 |
Current international trends in the treatment of multiple sclerosis in children -impact of the COVID-19 pandemic |
Fredrik Sandesjö, Evangeline Wassmer, Kumaran Deiva, Maria Pia Amato, Tanuja Chitnis, Cheryl Hemingway, et al. (+6) Lauren Krupp, Daniela Pohl, Kevin Rostasy, Emanuelle Waubant, Brenda Banwell, Ronny Wickström |
80 |
[GO] |
2021―Sep―27 |
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation |
Nitin Kumar Sahi, Syed Muhammad Ali Abidi, Omar Salim, Roby Abraham, Seema Kalra, Adnan Al-Araji |
81 |
[GO] |
2021―Sep―17 |
Long COVID or post COVID-19 syndrome |
J. Lechner-Scott, M. Levy, C. Hawkes, A. Yeh, G. Giovannoni |
82 |
[GO] |
2021―Sep―13 |
Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed |
Abdorreza Naser Moghadasi |
83 |
[GO] |
2021―Sep―09 |
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis |
Frederik Novak, Anna Christine Nilsson, Christian Nielsen, Dorte K. Holm, Kamilla Østergaard, Anna Bystrup, et al. (+13) Keld-Erik Byg, Isik S. Johansen, Kristen Mittl, William Rowles, Kira Mcpolin, Collin Spencer, Sharon Sagan, Chloe Gerungan, Michael R. Wilson, Scott S. Zamvil, Riley Bove, Joseph J. Sabatino, Tobias Sejbaek |
84 |
[GO] |
2021―Aug―25 |
MENACTRIMS Practice Guideline for COVID-19 Vaccination in Patients with Multiple Sclerosis |
Bassem I Yamout, Magd Zakaria, Jihad Inshasi, Mohammad Al-Jumah, Maya Zeineddine, Maurice Dahdaleh, et al. (+3) Saeed Bohlega, Riadh Gouider, Raed Alroughani |
85 |
[GO] |
2021―Aug―16 |
COVID-19 severity and outcome in multiple sclerosis: results of a national, registry-based, matched cohort study |
Carlos A. Pérez, Guo-Qiang Zhang, Xiaojing Li, Yan Huang, John A. Lincoln, Rohini D. Samudralwar, et al. (+2) Rajesh K Gupta, John W. Lindsey |
86 |
[GO] |
2021―Aug―08 |
Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab |
Rosetta Pedotti, Erwan Muros-Le Rouzic, Catarina Raposo, Sven Schippling, Nikki Jessop |
87 |
[GO] |
2021―Aug―02 |
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases |
Itay Lotan, Gabriela Romanow, Michael Levy |
88 |
[GO] |
2021―Jul―31 |
The comparison of fatigue, sleep quality, physical activity, quality of life, and psychological status in multiple sclerosis patients with or without COVID-19 |
Mehmet Özkeskin, Fatih Özden, Bedriye Karaman, Özgül Ekmekçi, Nur Yüceyar |
89 |
[GO] |
2021―Jul―27 |
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis - UK MS Register Survey |
Yun Huang, William J Rodgers, Rodden M Middleton, Aravindhan Baheerathan, Katherine A Tuite-Dalton, David V Ford, et al. (+2) Richard Nicholas, MS Register Research Group |
90 |
[GO] |
2021―Jul―25 |
Coronavirus disease 2019 in Latin American patients with multiple sclerosis |
Yara D. Fragoso, Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Judith Steinberg, Irene Treviño-Frenk, et al. (+10) Ethel Ciampi, Maria Cecilia A. Vecino, Edgar P. Correa, Claudia Carcamo, Sidney Gomes, Maria Lucia V. Pimentel, Gutemberg A.C. Santos, Carlos Vrech, Thereza C.A. Winckler, Maria Pia Sormani |
91 |
[GO] |
2021―Jul―24 |
Cerebrospinal Fluid Cytokine, Chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19 |
Binh Ngo, Stacey A. Lapp, Benjamin Siegel, Vikash Patel, Laila Hussaini, Sonali Bora, et al. (+6) Bryan Philbrook, Kristin Weinschenk, Laura Wright, Evan J. Anderson, Christina A. Rostad, Grace Y. Gombolay |
92 |
[GO] |
2021―Jul―22 |
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021 |
Dawn M. Ehde, Michelle K. Roberts, Andrew T. Humbert, Tracy E. Herring, Kevin N. Alschuler |
93 |
[GO] |
2021―Jul―21 |
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers |
Marco Iannetta, Doriana Landi, Gaia Cola, Vincenzo Malagnino, Elisabetta Teti, Daniela Fraboni, et al. (+7) Francesco Buccisano, Sandro Grelli, Luigi Coppola, Laura Campogiani, Andreoni Massimo, Girolama Alessandra Marfia, Loredana Sarmati |
94 |
[GO] |
2021―Jul―19 |
Outcomes of COVID-19 Infection in Multiple Sclerosis and Related Conditions: One-Year Pandemic Experience of the Multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC) |
Sylvia Klineova, Asaff Harel, Rebecca Straus Farber, Tracy DeAngelis, Yinan Zhang, Roland Hentz, et al. (+5) Tung Ming Leung, Kathryn Fong, Tyler Smith, Richard Blanck, Lana Zhovtis-Ryerson |
95 |
[GO] |
2021―Jul―18 |
COVID-19 vaccines and multiple sclerosis disease-modifying therapies |
Gavin Giovannoni, Christopher H. Hawkes, Jeannette Lechner-Scott, Michael Levy, E. Ann Yeh, David Baker |
96 |
[GO] |
2021―Jul―16 |
Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis |
Lorna Galleguillos, Ricardo Alonso |
97 |
[GO] |
2021―Jul―15 |
HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES |
Jelena Drulovic, Jovana Ivanovic, Vanja Martinovic, Olivera Tamas, Nikola Veselinovic, Danica Cujic, et al. (+3) Marija Gnjatovic, Sarlota Mesaros, Tatjana Pekmezovic |
98 |
[GO] |
2021―Jul―13 |
Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting |
Geraldine G. Luetic, María Laura Menichini, Óscar Fernández |
99 |
[GO] |
2021―Jul―02 |
Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update |
Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka |
100 |
[GO] |
2021―Jul―02 |
Risk factors for COVID-19 infection in patients with multiple sclerosis: a nested case-control study |
Lauren Uhr, Hollie Schmidt, Farrah J. Mateen |
101 |
[GO] |
2021―Jul―02 |
Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic |
Judit Díaz-Díaz, Clara Isabel Ramirez, Marta Ortiz-Pica, Elena García-Yusta, Irene Gómez-Estevez, Celia Oreja-Guevara |
102 |
[GO] |
2021―Jun―30 |
Changes on the Health Care of People with Multiple Sclerosis from Latin America during the COVID-19 Pandemic |
Anibal Chertcoff, Johana Bauer, Berenice Anabel Silva, Mayra Aldecoa, María Bárbara Eizaguirre, Roberto Rodriguez, et al. (+23) Ana Chereque, María Lourdes Rodríguez Hert, Verónica Milanesi, Lourdes Morales, Melba Castellón, Suyapa Mejía Pineda, Flavia Ferrandina, Paula Henestroza, Margarita Ruiz Peraza, Fátima Vallecillo Rivas, Lucía Cedeño Lopez, Leticia Herrera, Marta Sosa, Verónica Cruchet Muñoz, Ana Silvia Barahona, Luz María Ramírez Gudiño, Susana Carballido, Clare Walton, Liesbet M Peeters, Nick Rijke, Orlando Garcea, Adriana Carrá, Ricardo Alonso |
103 |
[GO] |
2021―Jun―26 |
Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine |
Joana Moniz Dionísio, Mariana Santos, Ana Martins Rodrigues, André Rêgo, Joana Vítor, Sofia Delgado, et al. (+7) Rita Pinheiro, Pedro Neves, Carlos Figueiredo, José Bandeira Costa, José Vale, Vasco Salgado, Ângela Timóteo |
104 |
[GO] |
2021―Jun―24 |
Frequency and characteristics of falls in people living with and without multiple sclerosis during the COVID-19 pandemic: a cross-sectional online survey |
Tobia Zanotto, Mikaela L Frechette, Stephen R Koziel, Katherine L Hsieh, Jacob J Sosnoff |
105 |
[GO] |
2021―Jun―24 |
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in the Czech Republic |
Dominika Stastna, Ingrid Menkyova, Jiri Drahota, Aneta Mazouchova, Jana Adamkova, Radek Ampapa, et al. (+10) Marketa Grunermelova, Marek Peterka, Eva Recmanova, Petra Rockova, Matous Rous, Ivana Stetkarova, Martin Valis, Marta Vachova, Ivana Woznicova, Dana Horakova |
106 |
[GO] |
2021―Jun―02 |
Fear of COVID-19, problems accessing medical appointments, and subjective experience of disease progression, predict anxiety and depression reactions in patients with Multiple Sclerosis |
Broche-Pérez Yunier, Rodneys M. Jiménez-Morales, Laura Ortiz Monasterio-Ramos, Lázaro A. Vázquez-Gómez, Zoylen Fernández-Fleites |
107 |
[GO] |
2021―May―30 |
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series. |
Geraldine Luetic, María L. Menichini, Marcos Burgos, Ricardo Alonso, Edgar Carnero Contentti, Adriana Carrá, et al. (+3) Norma Deri, Judith Steinberg, Juan I. Rojas |
108 |
[GO] |
2021―May―30 |
A Commentary Letter on “Can Coronavirus Disease 2019 (COVID-19) Trigger Exacerbation of Multiple Sclerosis? A Retrospective Study” |
Nahad Sedaghat |
109 |
[GO] |
2021―May―27 |
The impact of COVID-19 home confinement on neuromuscular performance, functional capacity, and psychological state in Spanish people with Multiple Sclerosis |
Luis Andreu-Caravaca, Domingo J. Ramos-Campo, Linda H. Chung, Pedro Manonelles, Oriol Abellán-Aynés, Jacobo Á. Rubio-Arias |
110 |
[GO] |
2021―May―25 |
The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis |
CH Marck, A Hunter, B Heritage, L Gibbs, AG Kermode, DI Walker, YC Learmonth |
111 |
[GO] |
2021―May―24 |
Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: the relationship between perceived stress and quality of life |
Bengu Altunan, Aysun Unal, Ayhan Bingöl, Filiz Dilek, Derya Girgin |
112 |
[GO] |
2021―May―18 |
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis |
K. Allen-Philbey, A. Stennett, T. Begum, AC. Johnson, R. Dobson, G. Giovannoni, et al. (+7) S. Gnanapavan, M. Marta, I. Smets, B.P. Turner, D. Baker, J. Mathews, K. Schmierer |
113 |
[GO] |
2021―May―07 |
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: a case-control study |
William L. Conte |
114 |
[GO] |
2021―May―07 |
Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia |
Foziah Alshamrani, Hind Alnajashi, Mohammed Aljumah, Mohammad Almuaigel, Yaser Almalik, Seraj Makkawi, et al. (+9) Sadiq Alsalman, Mousa Almejally, Shireen Qureshi, Salman Aljarallah, Nuha AlKhawajah, Hanaa Kedah, Hessa Alotaibi, Jameelah Saeedi, Abdulla Alamri |
115 |
[GO] |
2021―May―05 |
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies |
Afagh Garjani, Rodden M Middleton, Rachael Hunter, Katherine A Tuite-Dalton, Alasdair Coles, Ruth Dobson, et al. (+8) Martin Duddy, Stella Hughes, Owen R Pearson, David Rog, Emma C Tallantyre, Roshan das Nair, Richard Nicholas, Nikos Evangelou |
116 |
[GO] |
2021―May―04 |
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab |
Fabio Buttari, Antonio Bruno, Ettore Dolcetti, Federica Azzolini, Paolo Bellantonio, Diego Centonze, Roberta Fantozzi |
117 |
[GO] |
2021―Apr―28 |
The course of COVID-19 infection in patients with multiple sclerosis - the experience of one center based on the population of Upper Silesia |
Maria Nowak-Kiczmer, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Bożena Adamczyk, Krzysztof Wierzbicki, Wojciech Bartman, Monika Adamczyk-Sowa |
118 |
[GO] |
2021―Apr―14 |
Can Coronavirus Disease 2019 (COVID-19) Trigger Exacerbation of Multiple Sclerosis? A Retrospective Study |
Mahdi Barzegar, Saeed Vaheb, Omid Mirmosayyeb, Alireze Afshari-Safavi, Nasim Nehzat, Vahid Shaygannejad |
119 |
[GO] |
2021―Mar―27 |
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update |
Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka |
120 |
[GO] |
2021―Mar―25 |
Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis |
Gauruv Bose, Kristin Galetta |
121 |
[GO] |
2021―Mar―21 |
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect? |
Masoud Etemadifar, Nahad Sedaghat, Ali Aghababaee, Parisa K Kargaran, Mohammad Reza Maracy, Mazdak Ganjalikhani-Hakemi, et al. (+5) Milad Rayani, Amir Parsa Abhari, Reza Khorvash, Mehri Salari, Hosein Nouri |
122 |
[GO] |
2021―Mar―21 |
COVID-19 and emerging spinal cord complications: A systematic review |
Ritwick Mondal, Shramana Deb, Gourav Shome, Upasana Ganguly, Durjoy Lahiri, Julián Benito-Leon |
123 |
[GO] |
2021―Mar―14 |
Sars-Cov-2 infection related inflammatory and demyelinating disease; a brief case series |
Nurhan Kaya Tutar, Sami Omerhoca, Eda Coban, Nilufer Kale |
124 |
[GO] |
2021―Mar―09 |
B cell therapy and the use of RNA-based COVID-19 vaccines |
Anastasia Vishnevetsky, Chris Hawkes, Jeannette Lechner-Scott, Gavin Giovannoni, Michael Levy |
125 |
[GO] |
2021―Mar―07 |
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America |
Ricardo Alonso, Berenice Silva, Orlando Garcea, Patricio E. Correa Diaz, Giordani Rodrigues dos Passos, Deyanira A. Ramirez Navarro, et al. (+48) Luis A. Garcia Valle, Luis C. Rodriguez Salinas, Laura Negrotto, Geraldine Luetic, Verónica A. Tkachuk, Jimena Míguez, Fernando Hamuy Diaz de Bedoya, Lorna Galleguillos Goiry, Nicia E. Ramírez Sánchez, Marcos Burgos, Judith Steinberg, Maria E. Balbuena, Priscilla Monterrey Alvarez, Pablo A. López, María C. Ysrraelit, Rosalba A. León, Aron Benzadon Cohen, Fernando Gracia, Omaira Molina, Magdalena Casas, Norma H. Deri, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, Dario Tavolini, Debora Nadur, Ana M. Toral Granda, Roberto Weiser, Fátima Pagani Cassará, Vladimiro Sinay, Claudia Cárcamo Rodríguez, Luciana G. Lazaro, María L. Menichini, Raúl Piedrabuena, Geraldine Orozco Escobar, Adriana Carrá, Anibal Chertcoff, Biany Santos Pujols, Carlos Vrech, Adriana Tarulla, René Carvajal, Carolina Mainella, Jefferson Becker, Liesbet M. Peeters, Clare Walton, Marina Alonso Serena, Sebastián Nuñez, Juan I. Rojas |
126 |
[GO] |
2021―Mar―07 |
Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients |
Filipa Serrazina, André Sobral Pinho, Gonçalo Cabral, Manuel Salavisa, Ana Sofia Correia |
127 |
[GO] |
2021―Feb―24 |
COVID-19 in a temporal relation to the onset of multiple sclerosis |
Yara D. Fragoso, Filippe A.S. Pacheco, Guilherme L. Silveira, Rodrigo A. Oliveira, Vitor M. Carvalho, Ana Luiza C. Martimbianco |
128 |
[GO] |
2021―Feb―23 |
Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study |
Yinan Zhang, Erin Staker, Gary Cutter, Stephen Krieger, Aaron E Miller |
129 |
[GO] |
2021―Feb―23 |
MOG-associated encephalitis following SARS-COV-2 Infection |
John Peters, Saleh Alhasan, Chantal B.F. Vogels, Nathan D. Grubaugh, Shelli Farhadian, Erin E. Longbrake |
130 |
[GO] |
2021―Feb―23 |
Immunotherapy Responsive SARS-CoV-2 Infection Exacerbating Opsoclonus Myoclonus Syndrome |
Sarah E. Wiegand, Wendy G. Mitchell, Jonathan D. Santoro |
131 |
[GO] |
2021―Jan―29 |
COVID-19 and Disease-Modifying Therapies in Patients with Demyelinating Diseases of the Central Nervous System: A Systematic Review |
Maryam Sharifian-Dorche, Mohammad Ali Sahraian, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Maryam Karaminia, et al. (+4) Alexander William Saveriano, Roberta La Piana, Jack P Antel, Paul Steven Giacomini |
132 |
[GO] |
2021―Jan―29 |
Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population |
Neda Ramezani, Fereshteh Ashtari, Elahe Abdi Bastami, Kimia Ghaderi, Sayed Mohsen Hosseini, Maryam Kazemi Naeini, et al. (+2) Fatemeh Rajabi, Iman Adibi |
133 |
[GO] |
2021―Jan―22 |
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States |
Dawn M. Ehde, Michelle K. Roberts, Tracy E. Herring, Kevin N. Alschuler |
134 |
[GO] |
2021―Jan―21 |
Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: case report and literature review. |
Rodríguez de Antonio(Luis Alberto), González Suárez(Inés), Fernández Barriuso(Inés), Rabasa Pérez(María) |
135 |
[GO] |
2021―Jan―19 |
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program? |
Stefano Gelibter, Mario Orrico, Massimo Filippi, Lucia Moiola |
136 |
[GO] |
2021―Jan―19 |
Development of SARS-CoV-2 IgM and IgG antibodies in a Relapsing Multiple Sclerosis patient on Ofatumumab |
Ramon E Flores-Gonzalez, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan, Silvia Delgado |
137 |
[GO] |
2021―Jan―14 |
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients |
Giulia Mallucci, Antonio Zito, Fausto Baldanti, Matteo Gastaldi, Beatrice Dal Fabbro, Diego Franciotta, Roberto Bergamaschi |
138 |
[GO] |
2021―Jan―02 |
COVID-19 in teriflunomide-treated patients with multiple sclerosis: a case report and literature review. |
Fioravante Capone, Francesco Motolese, Tiziano Luce, Mariagrazia Rossi, Alessandro Magliozzi, Vincenzo Di Lazzaro |
139 |
[GO] |
2020―Dec―30 |
COVID-19 in ocrelizumab-treated people with multiple sclerosis |
Richard Hughes, Louise Whitley, Kocho Fitovski, Hans-Martin Schneble, Erwan Muros, Annette Sauter, et al. (+6) Licinio Craveiro, Paul Dillon, Ulrike Bonati, Nikki Jessop, Rosetta Pedotti, Harold Koendgen |
140 |
[GO] |
2020―Dec―25 |
Longitudinally extensive transverse myelitis following acute COVID-19 infection |
Thibault Fumery, Coline Baudar, Michel Ossemann, Frédéric London |
141 |
[GO] |
2020―Dec―24 |
Pandemic Forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era |
Jacqueline A. Nicholas, Robert K Shin, Enrique Alvarez, Barry Hendin, Kavita V. Nair, Fred D. Lublin |
142 |
[GO] |
2020―Dec―21 |
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness |
Barbara Barun, Tereza Gabelić, Ivan Adamec, Antonija Babić, Hrvoje Lalić, Drago Batinić, et al. (+2) Magdalena Krbot Skorić, Mario Habek |
143 |
[GO] |
2020―Dec―19 |
Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: focus on Telemedicine |
Ricardo Alonso, René Carvajal, Mateus Boaventura, Lorna Galleguillos |
144 |
[GO] |
2020―Dec―01 |
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic |
Louise Rath, Minh Viet Bui, Julian Ellis, John Carey, Josephine Baker, Lisa Taylor, et al. (+12) Hasini Fernando, Nicola Taylor, Poppy Savage, Janene Richards, Michael Zhong, Tomas Kalincik, Olga Skibina, Robb Wesselingh, Ai-Lan Nguyen, Mastura Monif, Helmut Butzkueven, Anneke van der Walt |
145 |
[GO] |
2020―Nov―05 |
Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic |
Kevin N. Alschuler, Michelle K. Roberts, Tracy E. Herring, Dawn M. Ehde |
146 |
[GO] |
2020―Oct―27 |
Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey |
Alon Kalron, Mark Dolev, Michal Greenberg-Abrahami, Shay Menascu, Lior Frid, Sharon Avrech-Shezifi, et al. (+3) Gil Harari, David Magalashvili, Anat Achiron |
147 |
[GO] |
2020―Oct―27 |
Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection? |
Adriana Fernanda K. Vizuete, Carlos-Alberto Gonçalves |
148 |
[GO] |
2020―Oct―26 |
THE IMPACT OF SARS-COV 2 ON THE ANXIETY LEVELS OF SUBJECTS AND ON THE ANXIETY AND DEPRESSION LEVELS OF THEIR PARENTS |
Tugce Damla Dilek, Zehra Boybay, Nursena Kologlu, Oguzhan Tin, Serhat Güler, Sema Saltık |
149 |
[GO] |
2020―Oct―23 |
Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS |
Kevin N. Alschuler, Gloria von Geldern, Darren Ball, Kathleen Costello, Mark Skeen, Salim Chahin, Annette Wundes |
150 |
[GO] |
2020―Oct―21 |
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment |
Fabio Giuseppe Masuccio, Marianna Lo Re, Antonio Bertolotto, Marco Capobianco, Claudio Solaro |
151 |
[GO] |
2020―Oct―13 |
Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic? |
Farouk Talaat, Ismail Ramadan, Salma Aly, Eman Hamdy |
152 |
[GO] |
2020―Oct―03 |
Mental health status of Relapsing-Remitting Multiple Sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: a monocentric experience |
Aurora Zanghì, Emanuele D'Amico, Maria Luca, Marco Ciaorella, Lucia Basile, Francesco Patti |
153 |
[GO] |
2020―Sep―29 |
Could Sars-Cov2 affect MS progression? |
Arianna Di Stadio, Luigina Romani, Evanthia Bernitsas |
154 |
[GO] |
2020―Sep―28 |
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms |
Farnaz Nikbakht, Ali Mohammadkhanizadeh, Ekram Mohammadi |
155 |
[GO] |
2020―Sep―19 |
Impact of the COVID-19 Pandemic on the Health Care of >1,000 People Living with Multiple Sclerosis: A cross-sectional study |
Andre C. Vogel, Hollie Schmidt, Sara Loud, Robert McBurney, Farrah J. Mateen |
156 |
[GO] |
2020―Sep―16 |
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia |
Nabil Seery, Vivien Li, Ai-Lan Nguyen, Izanne Roos, Katherine A Buzzard, Roberts Atvars, et al. (+10) Nicola Taylor, Kelsey Tunnell, John Carey, Chris Dwyer, Hasini Fernandoa Lisa Taylor, Josephine Baker, Mark P Marriott, Trevor J Kilpatrick, Tomas Kalincik, Mastura Monif |
157 |
[GO] |
2020―Sep―03 |
Beyond COVID-19: do MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies ? |
Elisabeth Maillart, Caroline Papeix, Catherine Lubetzki, Thomas Roux, Valérie Pourcher, Céline Louapre |
158 |
[GO] |
2020―Sep―01 |
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report |
Naomi S. de Ruijter, Gerrit Kramer, Rob A.R. Gons, Gerald J.D. Hengstman |
159 |
[GO] |
2020―Aug―30 |
Normal antibody response after COVID-19 during treatment with cladribine |
Elisabeth G. Celius |
160 |
[GO] |
2020―Aug―29 |
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis |
Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Sara Ala, Abdorreza Naser Moghadasi |
161 |
[GO] |
2020―Aug―27 |
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets |
Dominic Jack, Axel Nolting, Andrew Galazka |
162 |
[GO] |
2020―Aug―20 |
Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes. |
Constanza Segamarchi, Berenice Silva, Patricia Saidon, Orlando Garcea, Ricardo Alonso |
163 |
[GO] |
2020―Aug―19 |
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients |
Vittorio Mantero, Lucia Abate, Roberto Balgera, Paola Basilico, Andrea Salmaggi, Christian Cordano |
164 |
[GO] |
2020―Aug―16 |
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice |
Marcello De Angelis, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia |
165 |
[GO] |
2020―Aug―10 |
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: insight to the immune response after COVID |
Celsi Fiorella, Galleguillos Lorna |
166 |
[GO] |
2020―Aug―04 |
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab |
Marco Iannetta, Novella Cesta, Christof Stingone, Vincenzo Malagnino, Elisabetta Teti, Pietro Vitale, et al. (+11) Giuseppe De Simone, Benedetta Rossi, Lorenzo Ansaldo, Mirko Compagno, Ilaria Spalliera, Andrea Di Lorenzo, Doriana Landi, Carolina Gabri Nicoletti, Girolama Alessandra Marfia, Massimo Andreoni, Loredana Sarmati |
167 |
[GO] |
2020―Jul―31 |
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients |
Malgorzata Kloc, Rafik M. Ghobrial |
168 |
[GO] |
2020―Jul―19 |
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod |
Giulia Mallucci, Antonio Zito, Beatrice Dal Fabbro, Roberto Bergamaschi |
169 |
[GO] |
2020―Jul―17 |
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab |
Eva Fernández-Díaz, Julia Gracia-Gil, Jose Gregorio García-García, María Palao, Carlos M Romero-Sánchez, Tomás Segura |
170 |
[GO] |
2020―Jul―16 |
Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak |
Aleksandar Stojanov, Marina Malobabic, Vuk Milosevic, Jelena Stojanov, Slobodan Vojinovic, Goran Stanojevic, Milos Stevic |
171 |
[GO] |
2020―Jul―12 |
COVID-19 in MS and NMOSD: A multicentric online national survey in Chile |
Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, Ramiro Fernández, Pía García, Claudio Navarrete-Asenjo, et al. (+6) José Miguel Tirapegui, Rubén Torres, Juan Polanco, Felipe Suárez, María José Cuello, Claudia Cárcamo |
172 |
[GO] |
2020―Jul―07 |
Multiple Sclerosis following SARS-CoV-2 infection |
M. Palao, E. Fernández-Díaz, J. Gracia-Gil, C.M. Romero-Sánchez, I. Díaz-Maroto, T. Segura |
173 |
[GO] |
2020―Jul―06 |
Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic |
Ljiljana Radulovic, Jevto Erakovic, Milovan Roganovic |
174 |
[GO] |
2020―Jul―04 |
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy |
Francesco Crescenzo, Damiano Marastoni, Chiara Bovo, Massimiliano Calabrese |
175 |
[GO] |
2020―Jul―03 |
Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources. |
S. Viswanathan |
176 |
[GO] |
2020―Jul―03 |
Adherence to social distancing and use of personal protective equipment and the risk of Sars-COV-2 infection in a cohort of patients with Multiple Sclerosis |
Landi D, Ponzano M, Nicoletti CG, Cecchi G, Cola G, Mataluni G, et al. (+3) Mercuri NB, Sormani MP, Marfia GA |
177 |
[GO] |
2020―Jun―30 |
The impact of COVID-19 on patients with Neuromyelitis Optica Spectrum Disorder; a pilot study |
Anna Tomczak, May H. Han |
178 |
[GO] |
2020―Jun―26 |
Negative SARS-CoV-2 Antibody Testing Following COVID-19 Infection in Two MS Patients Treated with Ocrelizumab |
Jeanine Rempe Thornton, Asaff Harel |
179 |
[GO] |
2020―Jun―24 |
A case of possible atypical demyelinating event of the central nervous system following COVID-19 |
Anahita Zoghi, Mahtab Ramezani, Mehrdad Roozbeh, Ilad Alavi Darzam, Mohammad Ali Sahraian |
180 |
[GO] |
2020―Jun―23 |
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report |
Matteo Lucchini, Assunta Bianco, Paola Del Giacomo, Chiara De Fino, Viviana Nociti, Massimiliano Mirabella |
181 |
[GO] |
2020―Jun―21 |
Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey |
Alonso Ricardo, Carnero Contentti Edgar, Silva Berenice Anabel, López Pablo Adrian, Garcea Orlando, Hamuy Fernando, et al. (+3) Rivera Víctor, Gracia Fernando, Rojas Juan Ignacio |
182 |
[GO] |
2020―Jun―20 |
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab |
Carlos Guevara, Eduardo Villa, Marcela Cifuentes, Rodrigo Naves, José de Grazia |
183 |
[GO] |
2020―Jun―20 |
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. |
WL Conte |
184 |
[GO] |
2020―Jun―16 |
Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina |
E Cristiano, L Patrucco, JI Rojas, S Nuñez |
185 |
[GO] |
2020―Jun―15 |
COVID-19 IN 7 MULTIPLE SCLEROSIS PATIENTS IN TREATMENT WITH ANTI-CD20 THERAPIES |
Dra. Virginia Meca-Lallana, Dra. Clara Aguirre, Dra. Laura Cardeñoso, Dra. Teresa Alarcon, Dr. José Vivancos |
186 |
[GO] |
2020―Jun―11 |
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab |
Jorge Matías-Guiu, Paloma Montero-Escribano, Vanesa Pytel, Jesús Porta-Etessam, Jordi A. Matias-Guiu |
187 |
[GO] |
2020―Jun―10 |
COVID-19 prevention and multiple sclerosis management: the SAFE pathway for the post-peak |
Antonio Buonomo, Vincenzo Brescia Morra, Emanuela Zappulo, Roberta Lanzillo, Ivan Gentile, Emma Montella, et al. (+3) Maria Triassi, Raffaele Palladino, Marcello Moccia |
188 |
[GO] |
2020―Jun―08 |
Characteristics of COVID-19 disease in multiple sclerosis patients |
Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Ghajarzadeh, Nasim Nehzat, Saeed Vaheb, Vahid Shaygannejad, Reza Vosoughi |
189 |
[GO] |
2020―Jun―03 |
Covid-19 in a Patient With Multiple Sclerosis Treated With Natalizumab: May the Blockade of Integrins Have a Protective Role? |
Clara Aguirre, Virginia Meca-Lallana, Ana Barrios-Blandino, Beatriz del Río, Jose Vivancos |
190 |
[GO] |
2020―Jun―03 |
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis |
Sara Salama, Gavin Giovannoni, Christopher H. Hawkes, Jeannette Lechner-Scott, Emmanuelle Waubant, Michael Levy |
191 |
[GO] |
2020―Jun―02 |
Evaluation of COVID-19 Infection in Patients with Neuromyelitis optica spectrum disorder (NMOSD): A Report from Iran |
Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Nasim Rezaeimanesh, Abdorreza Naser Moghadasi |
192 |
[GO] |
2020―Jun―02 |
Current and Emerging Therapeutics for Neuromyelitis Optica Spectrum Disorder: Relevance to the COVID-19 Pandemic |
Hesham Abboud, Crystal Zheng, Indrani Kar, Claire Kaori Chen, Crystal Sau, Alessandro Serra |
193 |
[GO] |
2020―Jun―02 |
ESTABLISHMENT OF A SAFETY PROTOCOL FOR THE ADMINISTRATION OF TREATMENTS IN MULTIPLE SCLEROSIS DURING THE SARS-CoV-2 PANDEMIC |
Virginia Meca-Lallana, Clara Aguirre, Laura Cardeñoso, Teresa Alarcon, Angels Figuerola-Tejerina, Beatriz del Río, et al. (+2) Miguel Ruiz Álvarez, José Vivancos |
194 |
[GO] |
2020―May―23 |
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic |
Mahsa Ghajarzadeh, Omid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, Saeed Vaheb, Vahid Shaygannejad, Amir-Hadi Maghzi |
195 |
[GO] |
2020―May―23 |
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations |
Carlos Guevara, Eduardo Villa, Carlos Silva Rosas, Violeta Diaz, Rodrigo Naves |
196 |
[GO] |
2020―May―19 |
Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis Optica spectrum disorder. |
Marina Creed, Enrique Ballesteros, L. John Greenfield Jr, Jaime Imitola |
197 |
[GO] |
2020―May―16 |
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series |
Richard Hughes, Rosetta Pedotti, Harold Koendgen |
198 |
[GO] |
2020―May―16 |
COVID-19 pandemic: the experience of a multiple sclerosis centre in Chile |
Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo |
199 |
[GO] |
2020―May―16 |
Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? |
Emin GEMCIOGLU, Mehmet DAVUTOGLU, Ese Ece OZDEMIR, Abdulsamet ERDEN |
200 |
[GO] |
2020―May―15 |
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab |
Kulachanya Suwanwongse, Nehad Shabarek |
201 |
[GO] |
2020―May―14 |
Knowledge regarding COVID-19 pandemic in patients with Multiple sclerosis (MS): A report from Iran |
Mohammad Ali Sahraian, Mohammad Reza Gheini, Nasim Rezaeimanesh, Mahsa Ghajarzadeh, Abdorreza Naser Moghadasi |
202 |
[GO] |
2020―May―13 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran |
Farinaz Safavi, Bardia Nourbakhsh, Amir Reza Azimi |
203 |
[GO] |
2020―May―12 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. |
David Baker, Sandra Amor, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni |
204 |
[GO] |
2020―May―08 |
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19 |
Cristina Valencia-Sanchez, Dean M. Wingerchuk |
205 |
[GO] |
2020―May―07 |
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain |
Paloma Montero-Escribano, Jorge Matías-Guiu, Patricia Gómez-Iglesias, Jesús Porta-Etessam, Vanesa Pytel, Jordi A. Matias-Guiu |
206 |
[GO] |
2020―May―06 |
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |
Christian Foerch, Lucie Friedauer, Boris Bauer, Timo Wolf, Elisabeth H. Adam |
207 |
[GO] |
2020―Apr―30 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment |
Konrad Rejdak, Paweł Grieb |
208 |
[GO] |
2020―Apr―30 |
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach |
Giovanna Borriello, Antonio Ianniello |
209 |
[GO] |
2020―Apr―30 |
Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients |
Fahimeh Haji Akhoundi, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi |
210 |
[GO] |
2020―Apr―22 |
Rethinking high-risk groups in COVID-19 |
Anastasia Vishnevetsky, Michael Levy |
211 |
[GO] |
2020―Apr―20 |
One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients |
Abdorreza Naser Moghadasi |
212 |
[GO] |
2020―Apr―18 |
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |
Gavin Giovannoni |
213 |
[GO] |
2020―Apr―18 |
The importance of being a Neurologist (during a dramatic pandemic) |
Stefano Gelibter |
214 |
[GO] |
2020―Apr―15 |
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? |
Giovanni Novi, Malgorzata Mikulska, Federica Briano, Federica Toscanini, Francesco Tazza, Antonio Uccelli, Matilde Inglese |
215 |
[GO] |
2020―Apr―05 |
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge |
Edgar Carnero Contentti, Jorge Correa |
216 |
[GO] |
2020―Mar―28 |
The COVID-19 pandemic and the use of MS disease-modifying therapies |
Gavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant, Julian Gold |